

Jeffrey A Cohen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2034013/jeffrey-a-cohen-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

149
papers

19,917
citations

46
h-index

141
g-index

160
ext. papers

23,885
ext. citations

9
avg, IF

6.47
L-index

#	Paper	IF	Citations
149	Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585211061343	5	2
148	Perspectives and experiences with COVID-19 vaccines in people with MS.. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022 , 8, 20552173221085242	2	0
147	Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585221078825	5	1
146	Treatment Challenges in Multiple Sclerosis - A Continued Role for Glatiramer Acetate?. <i>Frontiers in Neurology</i> , 2022 , 13, 844873	4.1	0
145	Women's Health in Multiple Sclerosis: A Scoping Review.. <i>Frontiers in Neurology</i> , 2021 , 12, 812147	4.1	1
144	Clinical features and outcomes of COVID-19 despite SARS-CoV-2 vaccination in people with multiple sclerosis.. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021 , 7, 20552173211057110	2.1	10
143	MRI findings in blinded trials should be available to treating physicians - No. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 814-815	5	1
142	Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 2219-2231	5	2
141	Multiple Sclerosis Wellness Shared Medical Appointment Model: A Pilot Study. <i>International Journal of MS Care</i> , 2021 , 23, 229-233	2.3	
140	Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 51, 102844	4	3
139	Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 48, 102673	4	3
138	Evolution of the Diagnostic Criteria in Multiple Sclerosis 2021 , 75-87		
137	Early age of onset predicts severity of visual impairment in patients with neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1749-1759	5	1
136	Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology. <i>Neurology: Clinical Practice</i> , 2021 , 11, 352-357	1.7	0
135	A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211035333	5	0
134	Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials. <i>European Journal of Neurology</i> , 2021 , 28, 3722-3730	6	2
133	Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis. <i>CNS Drugs</i> , 2021 , 35, 985-997	6.7	3

132	Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders. <i>Journal of Neurology</i> , 2021 , 1	5.5	1
131	Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions. <i>Lancet, The</i> , 2021 , 398, 1184-1194	4.0	16
130	The 2013 clinical course descriptors for multiple sclerosis: A clarification. <i>Neurology</i> , 2020 , 94, 1088-1092	6.5	37
129	Technology-enabled assessments to enhance multiple sclerosis clinical care and research. <i>Neurology: Clinical Practice</i> , 2020 , 10, 222-231	1.7	6
128	Continuing Clinical Research During Shelter-in-Place. <i>Annals of Neurology</i> , 2020 , 88, 658-660	9.4	2
127	Advances in oral immunomodulating therapies in relapsing multiple sclerosis. <i>Lancet Neurology, The</i> , 2020 , 19, 336-347	24.1	54
126	Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. <i>Contemporary Clinical Trials</i> , 2020 , 95, 106009	2.3	9
125	Palatal myoclonus, abnormal eye movements, and olivary hypertrophy in GAD65-related disorder. <i>Neurology</i> , 2020 , 94, 273-275	6.5	4
124	Technology-enabled comprehensive characterization of multiple sclerosis in clinical practice. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 38, 101525	4	7
123	Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 23-37	5	32
122	Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 46, 102454	4	11
121	COVID-19 in people with multiple sclerosis: A global data sharing initiative. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1157-1162	5	34
120	Multiple sclerosis management during the COVID-19 pandemic. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1163-1171	3	34
119	Ofatumumab versus Teriflunomide in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2020 , 383, 546-557	59.2	132
118	Long-term ocrelizumab in progressive multiple sclerosis. <i>Lancet Neurology, The</i> , 2020 , 19, 966-968	24.1	
117	Long-term prognostic value of longitudinal measurements of blood neurofilament levels. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	11
116	Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1581-1589	5	8
115	Intrinsic and Extrinsic Mechanisms of Thalamic Pathology in Multiple Sclerosis. <i>Annals of Neurology</i> , 2020 , 88, 81-92	9.4	18

114	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. <i>Lancet Neurology, The</i> , 2019 , 18, 1009-1020	24.1	96
113	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. <i>Lancet Neurology, The</i> , 2019 , 18, 1021-1033	24.1	98
112	Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019 , 6,	9.1	4
111	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology, The</i> , 2019 , 18, 185-197	24.1	74
110	Developing therapeutic strategies to promote myelin repair in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2019 , 19, 997-1013	4.3	11
109	Exploratory MRI measures after intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019 , 5, 2055217319856035	2	8
108	The emergence of follow-on disease-modifying therapies for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1560-1565	5	3
107	Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 845-854	4.7	46
106	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1255-1262	5	24
105	Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 36, 101335	4	4
104	Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. <i>Journal of the Neurological Sciences</i> , 2019 , 407, 116498	3.2	6
103	Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results. <i>Therapeutic Advances in Neurological Disorders</i> , 2019 , 12, 1756286419878324	6.6	31
102	Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data. <i>Neurology</i> , 2019 , 93, e1921-e1931	6.5	31
101	Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019 , 5, 2055217319887198	2	4
100	Pregnancy and multiple sclerosis: Risk of unplanned pregnancy and drug exposure in utero. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019 , 5, 2055217319891744	2	5
99	Movement disorders in early MS and related diseases: A prospective observational study. <i>Neurology: Clinical Practice</i> , 2019 , 9, 24-31	1.7	9
98	The FLUENT study design: investigating immune cell subset and neurofilament changes in patients with relapsing multiple sclerosis treated with fingolimod. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019 , 5, 2055217318819245	2	2
97	Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1781-1790	5	63

96	Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1605-1617	5	46
95	Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 601-609	5	7
94	Mesenchymal Stem Cell-derived Neural Progenitor Cells in Progressive Multiple Sclerosis: Great Expectations. <i>EBioMedicine</i> , 2018 , 29, 5-6	8.8	5
93	Feasibility of mesenchymal stem cell culture expansion for a phase I clinical trial in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018 , 4, 2055217318765288 ²		6
92	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <i>Lancet Neurology, The</i> , 2018 , 17, 162-173	24.1	2419
91	Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 501-511	5	58
90	Integrating multiple sclerosis guidelines into practice. <i>Lancet Neurology, The</i> , 2018 , 17, 658-660	24.1	4
89	Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers. <i>Neurology: Clinical Practice</i> , 2018 , 8, 292-301	1.7	19
88	The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1469-1484	5	37
87	Applying the 2017 McDonald diagnostic criteria for multiple sclerosis - AuthorsTreply. <i>Lancet Neurology, The</i> , 2018 , 17, 499-500	24.1	22
86	The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 94-105	5	56
85	Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 704-710	5	163
84	Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1909-1917	5	17
83	CNS disease diminishes the therapeutic functionality of bone marrow mesenchymal stem cells. <i>Experimental Neurology</i> , 2017 , 295, 222-232	5.7	12
82	Effect of Template Reporting of Brain MRIs for Multiple Sclerosis on Report Thoroughness and Neurologist-Rated Quality: Results of a Prospective Quality Improvement Project. <i>Journal of the American College of Radiology</i> , 2017 , 14, 371-379.e1	3.5	39
81	Clemastine fumarate for promotion of optic nerve remyelination. <i>Lancet, The</i> , 2017 , 390, 2421-2422	40	10
80	Clinical outcome measures for progressive MS trials. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1627-1635	5	27
79	Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program. <i>Therapeutics and Clinical Risk Management</i> , 2017 , 13, 1423-1437	2.9	17

78	Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. <i>Neurology</i> , 2017 , 89, 1107-1116	6.5	139
77	Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. <i>Neurology</i> , 2017 , 89, 1117-1126	6.5	175
76	Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2017 , 3, 2055-2173	2.17	195485
75	Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis. <i>Neurotherapeutics</i> , 2017 , 14, 859-873	6.4	68
74	Safety of monoclonal antibodies for the treatment of multiple sclerosis. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 89-100	4.1	24
73	Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. <i>Lancet, The</i> , 2017 , 389, 1357-1366	4.0	174
72	Cell-based therapeutic strategies for multiple sclerosis. <i>Brain</i> , 2017 , 140, 2776-2796	11.2	102
71	Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 468-75	5.5	109
70	Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β 1a in MS. <i>Neurology</i> , 2016 , 87, 1464-1472	6.5	21
69	Human Mesenchymal Stem Cells Impact Th17 and Th1 Responses Through a Prostaglandin E2 and Myeloid-Dependent Mechanism. <i>Stem Cells Translational Medicine</i> , 2016 , 5, 1506-1514	6.9	53
68	The challenge of comorbidity in clinical trials for multiple sclerosis. <i>Neurology</i> , 2016 , 86, 1437-1445	6.5	30
67	Recommendations for observational studies of comorbidity in multiple sclerosis. <i>Neurology</i> , 2016 , 86, 1446-1453	6.5	51
66	Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology, The</i> , 2016 , 15, 373-81	24.1	118
65	Multiple sclerosis: Fingolimod failure in progressive MS INFORMS future trials. <i>Nature Reviews Neurology</i> , 2016 , 12, 253-4	15	5
64	Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. <i>Neurology</i> , 2016 , 87, 1985-1992	6.5	38
63	Lack of magnetic resonance imaging lesion activity as a treatment target in multiple sclerosis: An evaluation using electronically collected outcomes. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 9, 129-34	4.34	3
62	Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 10, 44-52	4	36
61	The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: a systematic review. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 332-41	5	30

60	Vision and vision-related outcome measures in multiple sclerosis. <i>Brain</i> , 2015 , 138, 11-27	11.2	136
59	Sphingosine 1-phosphate receptor modulators in multiple sclerosis. <i>CNS Drugs</i> , 2015 , 29, 565-75	6.7	89
58	Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial. <i>JAMA Neurology</i> , 2015 , 72, 1433-41	17.2	50
57	A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 282-93	5	91
56	Experience with fingolimod in clinical practice. <i>International Journal of Neuroscience</i> , 2015 , 125, 678-85	2	25
55	Multiple sclerosis: Switching sides--fingolimod versus injectable MS therapies. <i>Nature Reviews Neurology</i> , 2015 , 11, 316-7	15	3
54	A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 263-81	5	203
53	Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. <i>Neurology</i> , 2015 , 84, 784-93	6.5	93
52	The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1704-13	5	34
51	Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings. <i>Multiple Sclerosis and Related Disorders</i> , 2014 , 3, 494-504	4	91
50	First-dose effects of fingolimod: Pooled safety data from three phase 3 studies. <i>Multiple Sclerosis and Related Disorders</i> , 2014 , 3, 629-38	4	58
49	Defining the clinical course of multiple sclerosis: the 2013 revisions. <i>Neurology</i> , 2014 , 83, 278-86	6.5	1632
48	Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. <i>Neurology</i> , 2014 , 82, 674-80	6.5	113
47	Improvement of internuclear ophthalmoparesis in multiple sclerosis with dalfampridine. <i>Neurology</i> , 2014 , 83, 192-4	6.5	13
46	Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. <i>Immunotherapy</i> , 2014 , 6, 249-59	5.8	16
45	Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. <i>Journal of Neurology</i> , 2013 , 260, 2023-32	5.5	72
44	Mesenchymal stem cell transplantation in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2013 , 333, 43-9	3.2	94
43	Fingolimod therapy for multiple sclerosis. <i>Seminars in Neurology</i> , 2013 , 33, 37-44	3.2	35

42	Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. <i>Lancet Neurology, The</i> , 2012 , 11, 467-76	24.1	174
41	Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. <i>Lancet, The</i> , 2012 , 380, 1819-28	40	834
40	Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. <i>Lancet, The</i> , 2012 , 380, 1829-39	40	827
39	Early tolerability and safety of fingolimod in clinical practice. <i>Journal of the Neurological Sciences</i> , 2012 , 323, 167-72	3.2	42
38	Multiple sclerosis: new insights in pathogenesis and novel therapeutics. <i>Annual Review of Medicine</i> , 2012 , 63, 389-404	17.4	55
37	Handbook of Multiple Sclerosis 2012 ,		9
36	Multiple sclerosis: advances in understanding pathogenesis and emergence of oral treatment options. <i>Lancet Neurology, The</i> , 2011 , 10, 4-5	24.1	8
35	Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. <i>Lancet Neurology, The</i> , 2011 , 10, 520-9	24.1	178
34	Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. <i>Annals of Neurology</i> , 2011 , 69, 75-82	9.4	53
33	Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. <i>Annals of Neurology</i> , 2011 , 69, 292-302	9.4	6480
32	Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. <i>Annals of Neurology</i> , 2011 , 69, 759-77	9.4	286
31	Potential mechanisms of efficacy and adverse effects in the use of fingolimod (FTY720). <i>Expert Review of Clinical Pharmacology</i> , 2011 , 4, 567-70	3.8	14
30	Fingolimod. <i>Neurology: Clinical Practice</i> , 2011 , 1, 61-65	1.7	5
29	Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , 2010 , 362, 402-15	59.2	1686
28	Emerging oral therapies in multiple sclerosis. <i>Current Neurology and Neuroscience Reports</i> , 2010 , 10, 381-86	15	15
27	Combination therapy in multiple sclerosis. <i>Lancet Neurology, The</i> , 2010 , 9, 299-308	24.1	91
26	Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis. <i>Annals of Neurology</i> , 2010 , 68, 540-5	9.4	60
25	Emerging therapies for relapsing multiple sclerosis. <i>Archives of Neurology</i> , 2009 , 66, 821-8		24

24	The future of multiple sclerosis treatment. <i>Journal of the Neurological Sciences</i> , 2009 , 277 Suppl 1, S55-61.2		5
23	Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 383-90	5	428
22	How effective is intravenous immunoglobulin for the treatment of relapsing-remitting multiple sclerosis?. <i>Nature Clinical Practice Neurology</i> , 2008 , 4, 588-9		7
21	Multiple sclerosis symptom management. <i>Expert Review of Neurotherapeutics</i> , 2007 , 7, 1213-22	4.3	32
20	Appraisal of the multiple sclerosis functional composite. <i>Expert Review of Neurotherapeutics</i> , 2003 , 3, 335-41	4.3	1
19	Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. <i>Archives of Neurology</i> , 2001 , 58, 961-7		136
18	The potential for vigabatrin-induced intramyelinic edema in humans. <i>Epilepsia</i> , 2000 , 41, 148-57	6.4	63
17	Multiple sclerosis, porphyria-like symptoms, and a history of iron deficiency anemia in a family of Scottish descent. <i>American Journal of Medical Genetics Part A</i> , 1999 , 86, 194-6		12
16	Newer versus older treatments for relapsing-remitting multiple sclerosis. <i>Drug Safety</i> , 1996 , 14, 121-30	5.1	5
15	Ligand Binding to the Cell-Surface Receptor for Reovirus Type 3 Alters Schwann Cell Growth and Function. <i>Annals of the New York Academy of Sciences</i> , 1990 , 605, 412-415	6.5	
14	A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. <i>Nature</i> , 1989 , 339, 230-1	50.4	404
13	Truncal ataxia presumably due to malignant spinal cord compression. <i>Annals of Neurology</i> , 1987 , 21, 511-24		24
12	Measures of neurological impairment and disability in multiple sclerosis56-64		
11	Assessment of neuropsychological function in multiple sclerosis65-78		
10	Measurement of CNS atrophy128-149		1
9	The use of MRI in multiple sclerosis clinical trials198-212		
8	Interferon beta to treat multiple sclerosis300-314		
7	Treatment for patients with primary progressive multiple sclerosis604-613		

6 Management of pediatric multiple sclerosis632-644

5 Management of medical comorbidities in patients with multiple sclerosis714-723

4 Fingolimod to treat multiple sclerosis370-386

3 Aspects of multiple sclerosis that relate to experimental therapeutics1-11

2 Confirming a Historical Diagnosis of Multiple Sclerosis: Challenges and Recommendations.
Neurology: Clinical Practice,10.1212/CPJ.0000000000001149

1.7 1

1 Disease-modifying therapy for multiple sclerosis in clinical practice583-603